References
- Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992; 14(Suppl 1)S43–S53
- von Eiff M., Fahrenkamp A., Roos N., Fegler W., van de Loo J. Hepatosplenic candidosis‐a late manifestation of Candida septicemia. Mycoses 1990; 33: 283–290
- Blade J., Lopez‐Guillermo A., Rozman C., et al. Chronic systemic candidiasis in acute leukemia. Ann Hematol 1992; 64: 240–244
- Armstrong D. Treatment of opportunistic fungal infections. Clin Infect Dis 1993; 16: 1–7
- de Repentigny L. Serodiagnosis of candidiasis, aspergillosis and cryptococcosis. Clin Infect Dis 1992; 14(Suppl 1)Sll–12
- Meyer R. D. Current role of therapy with amphotericin B. Clin Infect Dis 1992; 14(Suppl 1)S154–S160
- Flannery M. T., Simmons D. B., Saba H., et al. Fluconazole in the treatment of hepatosplenic candidiasis. Arch Int Med 1992; 152: 406–408
- Anaissie E., Bodey G. P., Kantarjian H., et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991; 91: 142–150
- Wingard J. R. The use of fluconazole prophylaxis in patients with chemotherapy induced neutropenia. Leukaemia and Lymphoma 1992; 8: 353–359
- Bishop J. F., Mathews J. P., Young G. A., et al. A randomized study of high‐dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710–1717
- Bow E. J., Loewen R., Cheang M. S., Schacter B. Invasive fungal disease in adults undergoing remission‐induction therapy for AML: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995; 21: 361–369
- Cole G. T., Lynn K. T., Seshan K. R., et al. Evaluation of a murine model of hepatic candidiasis. J. Clin. Microbiol. 1990; 28: 1828–1841
- Sandovsky‐Losica H., Barr‐Nea L., Segal E. Fatal systemic candidiasis of gastrointestinal origin: an experimental model in mice compromised by anti‐cancer treatment. J Med Vet My col 1992; 303: 219–231
- Walsh T. J., Lee I. W., Roulides E., et al. Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases. Clin Infect Dis 1992; 14(Suppl 1)S139–S147
- Nohmi T., Abe S., Tansho S., Yamaguchi H. Supression of anti‐candida activity of murine and human neutrophils by glucocortcoids. Microbiol. Immunol 1994; 38: 977–982
- Heidenreich S., Kubis T., Schmidt M., Fegler W. Glucocorticoid‐induced alterations of monocyte defense mechanisms against Candida albicans. Cellular Immunology 1994; 157: 320–327
- Sayer H. G., Longton G., Bowden R., Pepe M., Storb R. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft‐versus‐host disease prevention. Blood 1994; 84: 1328–1332
- Winston D. J., Chandrasekar P. H., Lazarus H. M., et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann Intern Med 1993; 118: 495–503
- Goodman J. L., Winston D. J., Greenfield R. A., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–851
- Bodey G. P., Anaissie E. J., Elting L. S., et al. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994; 73: 2099–2106
- Goodrich J. M., Reed E. C., Mori M., et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J.I.D. 1991; 164: 731–740
- Bjerke J. W., Meyers J. D., Bowden R. A. Hepatosplenic candidiasis‐a contraindication to marrow transplantation?. Blood 1994; 84: 2811–2814
- Katayama K., Koizumi S., Yamagami M., et al. Successful peritransplant therapy in children with active hepatosplenic candidiasis. Int J. Hematol 1994; 59: 125–130